Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term antibody persistence after Hib-MenC booster in toddlers previously primed in studies 103974 and 104056
2006-006460-32Phase 4Completed
- Sponsor
- GSK
- Start
- Mar 2007
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Hib-MenC-TT in Haemophilus influenzae type b disease (Hib) and meningococcal group C disease (3 arms), sponsored by GSK. Primary endpoints: Antibody persistence at 12 months after booster, Antibody persistence at 24 months after booster and 2 more. Started Mar 2007; status: completed.
02
Drugs
Hib-MenC-TT
03
Conditions
Haemophilus influenzae type b disease (Hib)meningococcal group C disease
Beyond the preview
Go deeper on 2006-006460-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006460-32.